Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Dermatologic 2Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 76Neoplasms 28Lung Neoplasms 24Neoplasm Metastasis 12Mesothelioma, Malignant 11Mesothelioma 10Colorectal Neoplasms 10Ovarian Neoplasms 6Unspecified Adult Solid Tumor, Protocol Specific 5Small Cell Lung Carcinoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Melanoma 5Head and Neck Neoplasms 5Breast Neoplasms 5Adenocarcinoma of Lung 5Pancreatic Neoplasms 4Carcinoma 4Advanced Cancer 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Meningeal Carcinomatosis 3Lymphoma, Non-Hodgkin 3Lymphoma 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Advanced Solid Tumors 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2

Interventions

pembrolizumab 47Nivolumab 34Sunitinib 18Cyclophosphamide 18Everolimus 17Ipilimumab 15cabozantinib 14pazopanib 13Bevacizumab 13fludarabine 12atezolizumab 11temsirolimus 10Magnetic Resonance Spectroscopy 10Sorafenib 9aldesleukin 8Specimen Handling 8Paclitaxel 8Sirolimus 7CTLA-4 Antigen 7Axitinib 7belzutifan 6Radiosurgery 6Oxaliplatin 6Interleukin-2 6Fluorouracil 6spartalizumab 5avelumab 5Leucovorin 5Irinotecan 5Docetaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Renal Cell × Pemetrexed × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06839105 2025-05-31

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Recruiting
214 enrolled
DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡